MKI67 and neoplasm: Following the mentioned targeted therapy, the primary tumour regressed to a non-palpable state, while residual BT474-M1 lesions, contained GFP+ cells with a very low Ki-67 proliferation index (2% as opposed to 25% for the injected primary tumour cells) [20].